Essential Biomarkers & Genetic Alterations Evaluated
Precision oncology requires rigorous verification of somatic mutations, protein expression, and genomic signatures before finalizing a treatment protocol.
RECIST 1.1 Objective Tumor Measurement
Rigorous unidimensional measurement of target lesions to distinguish partial response, stable disease, and true disease progression.
Multiparametric MRI (mpMRI) Protocols
Diffusion-weighted imaging (DWI) and dynamic contrast-enhanced (DCE) analysis for prostate (PI-RADS), liver (LI-RADS), and rectal staging.
PET-CT SUVmax & Metabolic Response (PERCIST)
Assessing functional metabolic activity before and after therapy; distinguishes scar tissue from active viable malignancy.
Vascular Infiltration & Surgical Planes
Evaluates celiac axis, superior mesenteric artery/vein, and portal vein abutment for pancreatic, colorectal, and liver tumors.
Brain MRI Thin-Slice Contrast Protocols
Detects millimeter-sized cerebral metastases that dictate stereotactic radiosurgery vs observation.
Critical Treatment Decisions Addressed in Your Review
Our multidisciplinary panel examines your case from medical oncology, surgical, and radiation oncology angles to address these pivotal questions:
Resectable vs Locally Advanced / Unresectable
Confirming whether vascular invasion is borderline and can be converted to clear margins following neoadjuvant therapy.
True Recurrence vs Post-Radiation Necrosis
Using advanced perfusion MRI and metabolic PET to differentiate necrotic tissue breakdown from viable recurrent tumor.
Immunotherapy Pseudo-Progression vs Failure
Preventing premature discontinuation of life-saving checkpoint inhibitors due to transient immune cell infiltration mimicking tumor growth.
Biopsy Target Selection
Identifying the safest, highest-yield hypermetabolic lesion for percutaneous CT or ultrasound-guided biopsy.
Records Required for Radiology Review Second Opinion
Upload your files online. Our team coordinates directly with your hospital if records are incomplete.
Pathology & Biopsy Reports
Complete histopathology, tumor margin documentation, and formal IHC score sheets.
Raw DICOM Scans
CT, MRI, PET-CT discs or digital cloud download links (not just radiologist text summaries).
Genomic & NGS Panels
FoundationOne, Guardant, Tempus, or specialized assay reports (e.g. Oncotype, Decipher).
Frequently Asked Questions: Radiology Review
Clear clinical answers regarding diagnostic accuracy, surgical options, and biomarker interpretation.
Related Second Opinion & Diagnostic Services
Cancer decisions intersect pathology, radiology, and adjacent disease subspecialties.
Cancer Pathology Second Opinion
Pathology is the foundational blueprint of every cancer diagnosis, yet it is inherently interpretive. Major peer-reviewed medical studies document that 15% to 30% of second-look pathology reviews uncover diagnostic discordance: benign conditions mistaken for malignant tumors, incorrect tumor staging, missed lymphovascular invasion, or discordant hormone receptor/HER2 status that profoundly alters systemic treatment.
Lung Cancer Second Opinion
Advanced Non-Small Cell Lung Cancer (NSCLC) management hinges completely on comprehensive genomic profiling. Patients frequently start standard chemotherapy and immunotherapy before complete NGS results return, which can cause severe toxicities if an unspotted EGFR or ALK driver is present. A specialized lung second opinion verifies NGS adequacy, evaluates liquid vs tissue biopsy discordance, and refines PET-CT / EBUS mediastinal nodal staging.
Prostate Cancer Second Opinion
Prostate cancer is characterized by widespread overtreatment of indolent tumors and undertreatment of aggressive variants. Central pathology re-evaluation modifies the assigned Gleason score or ISUP Grade Group in up to 25% of cases. A second opinion integrates multiparametric MRI (PI-RADS v2.1), Decipher / Prolaris genomic testing, and PSMA PET-CT to determine whether active surveillance, robotic prostatectomy, focal therapy, or SBRT is the optimal pathway.
Colorectal Cancer Second Opinion
Colorectal cancer treatment branches drastically depending on tumor sidedness, microsatellite instability (MSI/dMMR), extended RAS/BRAF mutations, and HER2 amplification. In rectal cancer, Total Neoadjuvant Therapy (TNT) and watch-and-wait non-operative management can preserve sphincter function. In metastatic disease, aggressive multidisciplinary resection of colorectal liver metastases can achieve long-term cure in up to 35% of patients.
Complete Second Opinion Guide
Compare multidisciplinary reviews, read about record transfer logistics, and review transparent $450 flat pricing.
Get an Independent Second Opinion on Your Radiology Review Diagnosis
Upload your biopsy pathology slides, NGS reports, and DICOM scans. Receive a comprehensive multidisciplinary written report and staging audit within 12 to 72 hours.